Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Consequences of VHL Loss on Global DNA Methylome.

Robinson CM, Lefebvre F, Poon BP, Bousard A, Fan X, Lathrop M, Tost J, Kim WY, Riazalhosseini Y, Ohh M.

Sci Rep. 2018 Feb 20;8(1):3313. doi: 10.1038/s41598-018-21524-5.

2.

The HIF and other quandaries in VHL disease.

Tarade D, Ohh M.

Oncogene. 2018 Jan 11;37(2):139-147. doi: 10.1038/onc.2017.338. Epub 2017 Sep 18. Review.

PMID:
28925400
3.

A Late G1 Lipid Checkpoint That Is Dysregulated in Clear Cell Renal Carcinoma Cells.

Patel D, Salloum D, Saqcena M, Chatterjee A, Mroz V, Ohh M, Foster DA.

J Biol Chem. 2017 Jan 20;292(3):936-944. doi: 10.1074/jbc.M116.757864. Epub 2016 Dec 12.

4.

Effects of herbal medicine on human uterine tumor-bearing nude mice.

Ohh MH, Kim SJ, Han JK, Pak SC, Chee KM.

J Intercult Ethnopharmacol. 2016 Sep 25;5(4):422-426. eCollection 2016 Sep-Dec.

5.

Hydroxylation-Dependent Interaction of Substrates to the Von Hippel-Lindau Tumor Suppressor Protein (VHL).

Heir P, Ohh M.

Methods Mol Biol. 2016;1458:87-94. doi: 10.1007/978-1-4939-3801-8_7.

PMID:
27581016
6.

New structural and functional insight into the regulation of Ras.

Kano Y, Cook JD, Lee JE, Ohh M.

Semin Cell Dev Biol. 2016 Oct;58:70-8. doi: 10.1016/j.semcdb.2016.06.006. Epub 2016 Jun 11. Review.

PMID:
27297135
7.

Effects of Dietary Supplementation with Astaxanthin on Histamine Induced Lesions in the Gizzard and Proventriculus of Broiler Chicks.

Ohh MH, Kim S, Pak SC, Chee KM.

Asian-Australas J Anim Sci. 2016 Jun;29(6):672-8. doi: 10.5713/ajas.15.1020. Epub 2016 Jan 29.

8.

Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling.

Heir P, Srikumar T, Bikopoulos G, Bunda S, Poon BP, Lee JE, Raught B, Ohh M.

J Biol Chem. 2016 Apr 1;291(14):7357-72. doi: 10.1074/jbc.M115.694562. Epub 2016 Feb 4.

9.

Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis.

Bunda S, Burrell K, Heir P, Zeng L, Alamsahebpour A, Kano Y, Raught B, Zhang ZY, Zadeh G, Ohh M.

Nat Commun. 2015 Nov 30;6:8859. doi: 10.1038/ncomms9859.

10.

Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation.

Bunda S, Heir P, Srikumar T, Cook JD, Burrell K, Kano Y, Lee JE, Zadeh G, Raught B, Ohh M.

Proc Natl Acad Sci U S A. 2014 Sep 9;111(36):E3785-94. doi: 10.1073/pnas.1406559111. Epub 2014 Aug 25.

11.

The multifaceted von Hippel-Lindau tumour suppressor protein.

Robinson CM, Ohh M.

FEBS Lett. 2014 Aug 19;588(16):2704-11. doi: 10.1016/j.febslet.2014.02.026. Epub 2014 Feb 25. Review.

12.

Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway.

Bunda S, Qin K, Kommaraju K, Heir P, Ohh M.

Oncogene. 2015 Feb 5;34(6):789-97. doi: 10.1038/onc.2013.596. Epub 2014 Jan 27.

PMID:
24469048
13.

SOCS-1 mediates ubiquitylation and degradation of GM-CSF receptor.

Bunda S, Kommaraju K, Heir P, Ohh M.

PLoS One. 2013 Sep 26;8(9):e76370. doi: 10.1371/journal.pone.0076370. eCollection 2013.

14.

K63-ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair.

Metcalf JL, Bradshaw PS, Komosa M, Greer SN, Stephen Meyn M, Ohh M.

Oncogene. 2014 Feb 20;33(8):1055-65. doi: 10.1038/onc.2013.22. Epub 2013 Mar 4.

PMID:
23455319
15.

DCNL1 functions as a substrate sensor and activator of cullin 2-RING ligase.

Heir P, Sufan RI, Greer SN, Poon BP, Lee JE, Ohh M.

Mol Cell Biol. 2013 Apr;33(8):1621-31. doi: 10.1128/MCB.01342-12. Epub 2013 Feb 11.

16.

Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.

Bunda S, Kang MW, Sybingco SS, Weng J, Favre H, Shin DH, Irwin MS, Loh ML, Ohh M.

Cancer Res. 2013 Apr 15;73(8):2540-50. doi: 10.1158/0008-5472.CAN-12-3425. Epub 2013 Feb 11.

17.

Functional importance of Dicer protein in the adaptive cellular response to hypoxia.

Ho JJ, Metcalf JL, Yan MS, Turgeon PJ, Wang JJ, Chalsev M, Petruzziello-Pellegrini TN, Tsui AK, He JZ, Dhamko H, Man HS, Robb GB, Teh BT, Ohh M, Marsden PA.

J Biol Chem. 2012 Aug 17;287(34):29003-20. doi: 10.1074/jbc.M112.373365. Epub 2012 Jun 28.

18.

The updated biology of hypoxia-inducible factor.

Greer SN, Metcalf JL, Wang Y, Ohh M.

EMBO J. 2012 May 30;31(11):2448-60. doi: 10.1038/emboj.2012.125. Epub 2012 May 4. Review.

19.

Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1.

Wang Y, Roche O, Xu C, Moriyama EH, Heir P, Chung J, Roos FC, Chen Y, Finak G, Milosevic M, Wilson BC, Teh BT, Park M, Irwin MS, Ohh M.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):4892-7. doi: 10.1073/pnas.1112129109. Epub 2012 Mar 12.

20.

Tumor strengths and frailties: Cancer SUMmOns Otto's metabolism.

Ohh M.

Nat Med. 2012 Jan 6;18(1):30-1. doi: 10.1038/nm.2631. No abstract available.

PMID:
22227664
21.

Transcriptional regulation of genes via hypoxia-inducible factor.

Roche O, Ohh M.

Methods Mol Biol. 2012;809:189-99. doi: 10.1007/978-1-61779-376-9_13.

PMID:
22113277
22.

Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.

Russell RC, Sufan RI, Zhou B, Heir P, Bunda S, Sybingco SS, Greer SN, Roche O, Heathcote SA, Chow VW, Boba LM, Richmond TD, Hickey MM, Barber DL, Cheresh DA, Simon MC, Irwin MS, Kim WY, Ohh M.

Nat Med. 2011 Jun 19;17(7):845-53. doi: 10.1038/nm.2370.

23.

NEDD8 pathways in cancer, Sine Quibus Non.

Watson IR, Irwin MS, Ohh M.

Cancer Cell. 2011 Feb 15;19(2):168-76. doi: 10.1016/j.ccr.2011.01.002. Review.

24.

Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma.

Roos FC, Evans AJ, Brenner W, Wondergem B, Klomp J, Heir P, Roche O, Thomas C, Schimmel H, Furge KA, Teh BT, Thüroff JW, Hampel C, Ohh M.

Am J Pathol. 2011 Feb;178(2):853-60. doi: 10.1016/j.ajpath.2010.10.033.

25.

SATB2 augments ΔNp63α in head and neck squamous cell carcinoma.

Chung J, Lau J, Cheng LS, Grant RI, Robinson F, Ketela T, Reis PP, Roche O, Kamel-Reid S, Moffat J, Ohh M, Perez-Ordonez B, Kaplan DR, Irwin MS.

EMBO Rep. 2010 Oct;11(10):777-83. doi: 10.1038/embor.2010.125. Epub 2010 Sep 10.

26.

Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells.

Toschi A, Lee E, Thompson S, Gadir N, Yellen P, Drain CM, Ohh M, Foster DA.

Cancer Lett. 2010 Dec 18;299(1):72-9. doi: 10.1016/j.canlet.2010.08.006.

27.

Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.

Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Starý J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML.

Nat Genet. 2010 Sep;42(9):794-800. doi: 10.1038/ng.641. Epub 2010 Aug 8.

28.

Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus.

Roos FC, Roberts AM, Hwang II, Moriyama EH, Evans AJ, Sybingco S, Watson IR, Carneiro LA, Gedye C, Girardin SE, Ailles LE, Jewett MA, Milosevic M, Wilson BC, Bell JC, Der SD, Ohh M.

EMBO Mol Med. 2010 Jul;2(7):275-88. doi: 10.1002/emmm.201000081.

29.

Oxygen-mediated endocytosis in cancer.

Wang Y, Ohh M.

J Cell Mol Med. 2010 Mar;14(3):496-503. doi: 10.1111/j.1582-4934.2010.01016.x. Epub 2010 Jan 15. Review.

30.

Oxygen-independent degradation of HIF-alpha via bioengineered VHL tumour suppressor complex.

Sufan RI, Moriyama EH, Mariampillai A, Roche O, Evans AJ, Alajez NM, Vitkin IA, Yang VX, Liu FF, Wilson BC, Ohh M.

EMBO Mol Med. 2009 Apr;1(1):66-78. doi: 10.1002/emmm.200900004.

31.

Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.

Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M.

Cancer Res. 2009 Dec 1;69(23):9056-64. doi: 10.1158/0008-5472.CAN-09-1770. Epub 2009 Nov 17.

32.

Chemotherapy induces NEDP1-mediated destabilization of MDM2.

Watson IR, Li BK, Roche O, Blanch A, Ohh M, Irwin MS.

Oncogene. 2010 Jan 14;29(2):297-304. doi: 10.1038/onc.2009.314. Epub 2009 Sep 28.

PMID:
19784069
33.

Regulation of endocytosis via the oxygen-sensing pathway.

Wang Y, Roche O, Yan MS, Finak G, Evans AJ, Metcalf JL, Hast BE, Hanna SC, Wondergem B, Furge KA, Irwin MS, Kim WY, Teh BT, Grinstein S, Park M, Marsden PA, Ohh M.

Nat Med. 2009 Mar;15(3):319-24. doi: 10.1038/nm.1922. Epub 2009 Mar 1.

PMID:
19252501
34.

Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.

Toschi A, Lee E, Gadir N, Ohh M, Foster DA.

J Biol Chem. 2008 Dec 12;283(50):34495-9. doi: 10.1074/jbc.C800170200. Epub 2008 Oct 22.

35.

Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated [corrected] oxygen-sensing response.

Koeman JM, Russell RC, Tan MH, Petillo D, Westphal M, Koelzer K, Metcalf JL, Zhang Z, Matsuda D, Dykema KJ, Houseman HL, Kort EJ, Furge LL, Kahnoski RJ, Richard S, Vieillefond A, Swiatek PJ, Teh BT, Ohh M, Furge KA.

PLoS Genet. 2008 Sep 5;4(9):e1000176. doi: 10.1371/journal.pgen.1000176. Erratum in: PLoS Genet. 2008 Jul;4(7). doi: 10.1371/annotation/7f57058f-cc02-45a6-bfab-a835619e3916.

36.

NEDD8 acts as a 'molecular switch' defining the functional selectivity of VHL.

Russell RC, Ohh M.

EMBO Rep. 2008 May;9(5):486-91. doi: 10.1038/embor.2008.19. Epub 2008 Mar 7.

37.

Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau.

Roberts AM, Ohh M.

Curr Opin Oncol. 2008 Jan;20(1):83-9. Review.

PMID:
18043261
38.

HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D.

Toschi A, Edelstein J, Rockwell P, Ohh M, Foster DA.

Oncogene. 2008 Apr 24;27(19):2746-53. Epub 2007 Nov 12.

PMID:
17998935
39.

Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression.

Maynard MA, Evans AJ, Shi W, Kim WY, Liu FF, Ohh M.

Cell Cycle. 2007 Nov 15;6(22):2810-6. Epub 2007 Aug 29.

PMID:
17998805
40.

Nuclear E-cadherin and VHL immunoreactivity are prognostic indicators of clear-cell renal cell carcinoma.

Gervais ML, Henry PC, Saravanan A, Burry TN, Gallie BL, Jewett MA, Hill RP, Evans AJ, Ohh M.

Lab Invest. 2007 Dec;87(12):1252-64. Epub 2007 Oct 1.

41.

The role of hypoxia-inducible factors in cancer.

Maynard MA, Ohh M.

Cell Mol Life Sci. 2007 Aug;64(16):2170-80. Review.

PMID:
17514355
42.

Hypoxia-inducible expression of a natural cis-antisense transcript inhibits endothelial nitric-oxide synthase.

Fish JE, Matouk CC, Yeboah E, Bevan SC, Khan M, Patil K, Ohh M, Marsden PA.

J Biol Chem. 2007 May 25;282(21):15652-66. Epub 2007 Apr 2.

43.

The role of VHL in the regulation of E-cadherin: a new connection in an old pathway.

Russell RC, Ohh M.

Cell Cycle. 2007 Jan 1;6(1):56-9. Epub 2007 Jan 5. Review.

PMID:
17245122
44.
45.

VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail.

Evans AJ, Russell RC, Roche O, Burry TN, Fish JE, Chow VW, Kim WY, Saravanan A, Maynard MA, Gervais ML, Sufan RI, Roberts AM, Wilson LA, Betten M, Vandewalle C, Berx G, Marsden PA, Irwin MS, Teh BT, Jewett MA, Ohh M.

Mol Cell Biol. 2007 Jan;27(1):157-69. Epub 2006 Oct 23.

46.

Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function.

Watson IR, Blanch A, Lin DC, Ohh M, Irwin MS.

J Biol Chem. 2006 Nov 10;281(45):34096-103. Epub 2006 Sep 14.

47.
48.

Ubiquitin pathway in VHL cancer syndrome.

Ohh M.

Neoplasia. 2006 Aug;8(8):623-9. Review.

49.

pVHL's kryptonite: E2-EPF UCP.

Ohh M.

Cancer Cell. 2006 Aug;10(2):95-7. Review.

50.

von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms.

Calzada MJ, Esteban MA, Feijoo-Cuaresma M, Castellanos MC, Naranjo-Suárez S, Temes E, Méndez F, Yánez-Mo M, Ohh M, Landázuri MO.

Cancer Res. 2006 Feb 1;66(3):1553-60.

Supplemental Content

Support Center